Crescent Bi priced a public offering of 8,094,793 ordinary shares and 525,897 pre-funded warrants, expected to net roughly $115.9M (or ~$133.5M if the 30-day option is exercised).
Key Highlights:
- Company sold 8,094,793 ordinary shares at $14.50 and 525,897 pre-funded warrants at $14.499 to the public.
- Underwriters buy at $13.63 per share and $13.629 per pre-funded warrant; 30-day option for 1,293,103 additional shares.
- Net proceeds expected ~ $115.9M, or ~ $133.5M if the option is fully exercised, after fees and expenses.
- Each pre-funded warrant exercisable immediately at $0.001, non-expiring, with beneficial ownership limits (4.99%, 9.99% or 19.99%).
- Proceeds expected to fund operations, working capital and capex into the second half of 2028, subject to assumptions and risks.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.